Adjuvant chemoradiotherapy (CRT) plus pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC) with high risk of recurrence after neoadjuvant CRT plus surgery: A single-arm phase II study.

Guo J.C.TA-CHEN HUANGHUNG-YANG KUOLin, Chia-ChiChia-ChiLinHuang, Yen-LinYen-LinHuangFENG-MING HSUCHIA-HSIEN CHENGHsieh, Min-ShuMin-ShuHsiehHuang, Pei-MingPei-MingHuangLee, Jang-MingJang-MingLeeWu, Shu-LingShu-LingWuCHIH-HUNG HSU2026-01-202026-01-202024-01-200732183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/735482falseAdjuvant chemoradiotherapy (CRT) plus pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC) with high risk of recurrence after neoadjuvant CRT plus surgery: A single-arm phase II study.review article2-s2.0-105024542235